Table 1.

Characteristics of Included Studies

Study	Year	Country	2017 WHO estimated TB incidence (thousand)	Study design	No.	Age (yr)	BCG vaccinated (%)	PPD cutoff (mm)
Abreu et al. [19]	2016	Portugal	1.8	Prospective observational cohort	186	NR	100	5
Al-Taweel et al. [20]	2018	Canada	1.8	Prospective observational cohort	146	Mean 39.6	16.4	5 If on IST, 10 if high risk population, 15 if no risk
Andrisani et al. [21]	2013	Italy	3.8	Prospective observational cohort	92	Range 36–43	1.0	5 If on IST,10 others
Atanassova [13]a	2013	Bulgaria	1.5	Prospective observational cohort	34	Mean 39	100	NR
Bélard et al. [22]	2011	Denmark	0.26	Prospective observational cohort	89	Range 18–84	33.7	5 (BCG–), 10 (BCG+)
Çekiç et al. [23]	2015	Turkey	12	Retrospective observational cohort	76	Mean 42	NR	5
Fernandez et al. [14]a	2013	Spain	4.2	Prospective observational cohort	87	Mean 40	23.0	NR
Kurti et al. [12]	2015	Hungary	0.65	Prospective observational cohort	65	Mean 24	100	5
Latorre et al. [15]a	2011	Spain	4.2	Prospective observational cohort	13	NR	NR	NR
Mantzaris et al. [24]	2015	Greece	0.41	Prospective observational cohort	75	Mean 37	34.7	5 If IST, 10 others
Marano et al. [16]a	2015	USA	9.1	Prospective randomized control trial	1,283	Mean 40	39.0	5
Ministro et al. [17]a	2011	Portugal	1.8	Prospective observational cohort	24	NR	100	5
Papay et al. [25]a	2011	Austria	0.57	Prospective observational cohort	208	Mean 37	100	5 If IST, 10 others
Preda et al. [18]b	2016	Romania	13	Retrospective observational cohort	16	Mean 38	NR	5
Ramos et al. [26]	2013	Spain	4.2	Prospective observational cohort	25	Median 32	8.0	5
Wong et al. [11]	2014	China	790	Prospective observational cohort	69	NR	73.0	5

^aAbstract only.

^bLetter.

WHO, World Health Organization; TB, tuberculosis; PPD, protein derivative dose; NR, not recorded; IST, immunosuppressive therapy.